Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner

被引:195
作者
Skeen, Jennifer E.
Bhaskar, Prashanth T.
Chen, Chia-Chen
Chen, William S.
Peng, Xiao-ding
Nogueira, Veronique
Hahn-Windgassen, Annett
Kiyokawa, Hiroaki
Hay, Nissim [1 ]
机构
[1] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA
[2] Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA
关键词
D O I
10.1016/j.ccr.2006.08.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Akt contributes to tumorigenesis by inhibiting apoptosis. Here We establish that Akt is required for normal cell proliferation and susceptibility to oncogenesis independently of its antiapoptotic activity. Partial ablation of Akt activity by deleting Akt1 inhibits cell proliferation and oncogenesis. These effects are compounded by deleting both Akt1 and Akt2. In vivo, Akt1 null mice are resistant to MMTV-v-H-Ras-induced tumors and to skin carcinogenesis. Thus, partial ablation of Akt activity is sufficient to suppress tumorigenesis in vitro and in vivo. The effect of Akt deficiency on cell proliferation and oncogenesis is p53 independent but mTORC1 dependent. Surprisingly, upon mTORC1 hyperactivation, the reduction in Akt activity does not impair cell proliferation and susceptibility to oncogenic transformation; thus, Akt may mediate these processes exclusively via mTORC1.
引用
收藏
页码:269 / 280
页数:12
相关论文
共 42 条
[1]   The Akt kinase:: Molecular determinants of oncogenicity [J].
Aoki, M ;
Batista, O ;
Bellacosa, A ;
Tsichlis, P ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14950-14955
[2]   The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice [J].
Chen, Mei-Ling ;
Xu, Pei-Zhang ;
Peng, Xiao-Ding ;
Chen, William S. ;
Guzman, Grace ;
Yang, Ximing ;
Di Cristofano, Antonio ;
Pandolfi, Pier Paolo ;
Hay, Nissim .
GENES & DEVELOPMENT, 2006, 20 (12) :1569-1574
[3]   Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene [J].
Chen, WS ;
Xu, PZ ;
Gottlob, K ;
Chen, ML ;
Sokol, K ;
Shiyanova, T ;
Roninson, I ;
Weng, W ;
Suzuki, R ;
Tobe, K ;
Kadowaki, T ;
Hay, N .
GENES & DEVELOPMENT, 2001, 15 (17) :2203-2208
[4]   Pten is essential for embryonic development and tumour suppression [J].
Di Cristofano, A ;
Pesce, B ;
Cordon-Cardo, C ;
Pandolfi, PP .
NATURE GENETICS, 1998, 19 (04) :348-355
[5]   Targeting ras signalling pathways in cancer therapy [J].
Downward, J .
NATURE REVIEWS CANCER, 2003, 3 (01) :11-22
[6]   mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E [J].
Fingar, DC ;
Richardson, CJ ;
Tee, AR ;
Cheatham, L ;
Tsou, C ;
Blenis, J .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (01) :200-216
[7]   AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression [J].
Gera, JF ;
Mellinghoff, IK ;
Shi, YJ ;
Rettig, MB ;
Tran, C ;
Hsu, JH ;
Sawyers, CL ;
Lichtenstein, AK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (04) :2737-2746
[8]   4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway [J].
Gingras, AC ;
Kennedy, SG ;
O'Leary, MA ;
Sonenberg, N ;
Hay, N .
GENES & DEVELOPMENT, 1998, 12 (04) :502-513
[9]   Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity [J].
Hahn-Windgassen, A ;
Nogueira, V ;
Chen, CC ;
Skeen, JE ;
Sonenberg, N ;
Hay, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (37) :32081-32089
[10]   p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD [J].
Harada, H ;
Andersen, JS ;
Mann, M ;
Terada, N ;
Korsmeyer, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) :9666-9670